Issue Date: August 21, 2017 | Web Date: August 20, 2017
Janssen acquires Cerecor compound
Janssen Pharmaceuticals has acquired the selective kappa opioid receptor antagonist CERC-501 from Cerecor for $25 million plus a possible $20 million milestone payment. Baltimore-based Cerecor acquired CERC-501 from Eli Lilly & Co. in early 2015 and was developing the drug as a treatment for depression and substance use disorders. Late last year, Cerecor announced that CERC-501 failed in a trial as a treatment for nicotine withdrawal.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society